Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HCM 
HUTCHMED DRC (HCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: HCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $22.54
1 Year Target Price $22.54
| 9 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.07% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio 5.3 | 1Y Target Price 22.54 |
Price to earnings Ratio 5.3 | 1Y Target Price 22.54 | ||
Volume (30-day avg) 14 | Beta 0.51 | 52 Weeks Range 11.51 - 19.50 | Updated Date 12/5/2025 |
52 Weeks Range 11.51 - 19.50 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-14 | When - | Estimate - | Actual - |
Profitability
Profit Margin 77.53% | Operating Margin (TTM) -1.27% |
Management Effectiveness
Return on Assets (TTM) -0.81% | Return on Equity (TTM) 46.9% |
Valuation
Trailing PE 5.3 | Forward PE 50 | Enterprise Value 1237442434 | Price to Sales(TTM) 4.12 |
Enterprise Value 1237442434 | Price to Sales(TTM) 4.12 | ||
Enterprise Value to Revenue 2.05 | Enterprise Value to EBITDA 32.58 | Shares Outstanding 171871878 | Shares Floating 509015654 |
Shares Outstanding 171871878 | Shares Floating 509015654 | ||
Percent Insiders 0.12 | Percent Institutions 3.46 |
Upturn AI SWOT
HUTCHMED DRC
Company Overview
History and Background
HUTCHMED (China) Limited, previously known as Hutchison China MediTech, was founded in 2000. It initially focused on developing traditional Chinese medicine and has since evolved into a global biopharmaceutical company discovering and commercializing innovative therapies for cancer and immunological diseases.
Core Business Areas
- Oncology: HUTCHMED focuses on developing and commercializing novel oncology drugs. This segment includes research, development, and commercialization of targeted therapies and immunotherapies.
- Immunology: HUTCHMED has a pipeline of drug candidates targeting immunological diseases. This segment focuses on research and development of novel therapies for immunological disorders.
- Commercial Platform: HUTCHMED has a commercial platform in China that markets and distributes its own products and partner products.
Leadership and Structure
HUTCHMED is led by a team of experienced pharmaceutical executives and scientists. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Elunate (fruquintinib): Elunate is an oral VEGFR inhibitor approved in China for the treatment of metastatic colorectal cancer (mCRC). Global sales are on the rise and faces competition from other VEGF inhibitors and chemotherapies. Competitors include Bevacizumab (Avastin) from Roche.
- Sulanda (surufatinib): Sulanda is an angio-immuno kinase inhibitor approved in China and the US (as Savolitinib) for neuroendocrine tumors (NETs). Market share varies by region and faces competition from other targeted therapies and chemotherapies. Competitors include Sutent (Sunitinib) from Pfizer.
- Orpathys (savolitinib): Orpathys is a selective MET tyrosine kinase inhibitor conditionally approved in China for MET exon 14 skipping non-small cell lung cancer (NSCLC). Global sales are growing, but the drug faces competition from other targeted therapies. Competitors include Tepmetko (Tepotinib) from Merck KGaA.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The oncology market is particularly dynamic, with rapid innovation in targeted therapies and immunotherapies.
Positioning
HUTCHMED is positioned as an innovative biopharmaceutical company focused on developing and commercializing novel therapies for cancer and immunological diseases. Its competitive advantage lies in its strong R&D capabilities, its focus on Asian markets, and its strategic partnerships.
Total Addressable Market (TAM)
The global oncology and immunology markets are estimated to be worth hundreds of billions of dollars. HUTCHMED is positioned to capture a portion of these markets with its innovative pipeline and commercial platform.
Upturn SWOT Analysis
Strengths
- Innovative R&D pipeline
- Strong presence in Asian markets, particularly China
- Strategic partnerships with major pharmaceutical companies
- Growing commercial platform
- Experienced management team
Weaknesses
- High R&D costs and risks
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
- Limited product diversification
- Geographic concentration in China
Opportunities
- Expansion into new markets
- Development of new therapies for unmet medical needs
- Strategic acquisitions and partnerships
- Leveraging its commercial platform to market partner products
- Increase sales in US Market.
Threats
- Regulatory changes and pricing pressures
- Competition from generic drugs and biosimilars
- Clinical trial failures
- Economic downturns
- Changes in intellectual property laws
Competitors and Market Share
Key Competitors
- MRK
- PFE
- BMY
- AZN
- ROSYY
Competitive Landscape
HUTCHMED competes with larger pharmaceutical companies with greater resources, but it has a competitive advantage in its focus on Asian markets, and its pipeline of innovative therapies.
Major Acquisitions
No acquisitions to report for HutchMed
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: None
Growth Trajectory and Initiatives
Historical Growth: HUTCHMED has experienced rapid growth in recent years, driven by its pipeline of innovative therapies and its expansion into new markets.
Future Projections: Analyst projections suggest continued growth for HUTCHMED, driven by its pipeline of drug candidates and its commercial platform. Revenue is expected to increase as new products are launched and existing products gain market share.
Recent Initiatives: Recent strategic initiatives include expansion into new markets, strategic partnerships, and acquisitions.
Summary
HUTCHMED is an innovative biopharmaceutical company with a strong presence in China and a growing pipeline of novel therapies. Its focus on oncology and immunology positions it well in rapidly growing markets. Success depends on navigating regulatory hurdles, and commercializing its products effectively. Competition remains intense, requiring continuous innovation and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- HUTCHMED Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share and financial data are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HUTCHMED DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-03-17 | Acting CEO, CFO & Executive Director Mr. Chig Fung Cheng BEc, CA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1780 | Website https://www.hutch-med.com |
Full time employees 1780 | Website https://www.hutch-med.com | ||
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.